Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : SANGUINE CORP. (SGNC) -- Ignore unavailable to you. Want to Upgrade?

To: Turboe who wrote (2588)	7/5/1998 4:19:00 PM
From: Turboe	Read Replies (1) \| Respond to of 5402

Discounted at 40% for 20 years = $40,000,000,000.00 $40,000,000,000.00 / 21,000,000 share = $1,905.00 PER SHARE!

To: Turboe who wrote (2588)	7/5/1998 5:55:00 PM
From: Dixie7777	Read Replies (1) \| Respond to of 5402

The first eight questions for the valuation model were: 1) What is the total market potential for a universal cancer cure? 2) What kind of market share/penetration is Entremed expected to achieve? 3) When is Entremed's product expected to get to market? 4) How many shares will be outstanding the year the product hits markets and in each of the following 5 years? 5) What is the expected growth rate for the 5 year period following the introduction of the product into the market? 6) What will Entremed's net earnings after-tax (per share) be for those years. (Take into account the expenses, R&D costs and the fact that, if the product gets to market, the company is likely to earn a royalty on the sale of the product). In other words multiplying the answer to question 1 by the answer to question 2 does not equal the answer to question 6. 7) What P/E ratio would be appropriate to use for those years? 8) What discount rate would be appropriate to use to obtain a net present value? The next question is: 9) Why haven't you guys figured out a value for Entremed now that you have the model? Should I explain how it works? Now Forthright, for MY question: What is the current share price of Entremed and how does it relate to the share price developed in the valuation model?